NewAmsterdam Is Behind Another Try At CETP Inhibition, With Menarini’s Help

 
• By Joseph Haas

Years after failures by Merck, Lilly, Pfizer and Roche, NewAmsterdam hopes to bring a CETP inhibitor to market to lower cholesterol, and signs on with Menarini to lead commercial efforts in Europe.

cholesterol _181632251_1200.jpg
NewAmsterdam hopes to succeed where other firms failed in battling cholsterol

More from Deals

More from Business